Piper Sandler raised the firm’s price target on Viatris (VTRS) to $14 from $13 and keeps a Neutral rating on the shares following the firm’s annual healthcare conference. Piper continues to believe that to the extent that Viatris is going to see multiple expansion over time, it will take clinical/regulatory success on “innovative” brand assets.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTRS:
- Viatris price target raised to $12 from $11 at Barclays
- Viatris Inc. Reports Strong Q3 2024 Performance
- Early notable gainers among liquid option names on November 7th
- VTRS Earnings this Week: How Will it Perform?
- Lexicon signs licensing agreement with Viatris for sotagliflozin
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
